Dr. André-Guy Martin is a clinical radio-oncologist and brachytherapy specialist with the CHU de Québec radio-oncology Department. He is also a research associate at the Centre de recherche du CHU de Québec-Laval University, Oncology Axis, affiliated with the Laval University Cancer Research Center.
Having graduated with a PhD in radio-oncology from Laval University in 2002, he went on to train in brachytherapy and obtained a Fellowship in Brachytherapy from the Brigham and Women’s Hospital of the prestigious Harvard Medical School in Boston, Massachusetts, U.S.A. He also completed a master’s degree in experimental medicine (MSc) focusing on prostate brachytherapy through the I-125 implant. He has been practicing brachytherapy since, and is mainly interested in urological and digestive sites (brachytherapy of the esophagus and rectum).
His area of interest in research focuses mainly on imagery-guided, concentrated brachytherapy. Along with his team, he has added the new modalities of magnetic resonance imagery and is working on setting up an automated guidance system. Thanks to his previous training in pharmacology, he has developed new pharmacotherapeutic avenues (cytoreduction) to optimize the brachytherapy approach. He contributes to and locally directs the NRG protocols.
Very involved in his area of research, he is the co-editor of the Contemporary Journal of Brachytherapy. On the provincial level, he is treasurer for l’Association des radio-oncologues du Québec. Internationally, he also supports the Groupe Francophone de Radiothérapie en Urologie.
Hôtel-Dieu de Québec
11 Côte du Palais, Bureau 3342
Canada G1R 2J6
Data not available
Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial.Journal Article
Radiother Oncol, 155 , pp. 237-245, 2020, ISSN: 0167-8140.
Evaluating the impact of real-time multicriteria optimizers integrated with interactive plan navigation tools for HDR brachytherapy.Journal Article
Brachytherapy, 19 (5), pp. 607-617, 2020, ISSN: 1538-4721.
Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.Journal Article
Brachytherapy, 19 (5), pp. 584-588, 2020, ISSN: 1538-4721.
DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.Journal Article
Prostate, 80 (8), pp. 632-639, 2020, ISSN: 0270-4137.
Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal Cancer.Journal Article
Int J Radiat Oncol Biol Phys, 105 (5), pp. 1005-1011, 2019, ISSN: 0360-3016.
The association of intraprostatic calcifications and dosimetry parameters with biochemical control after permanent prostate implant.Journal Article
Brachytherapy, 18 (6), pp. 787-792, 2019, ISSN: 1538-4721.
A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer.Journal Article
Adv Radiat Oncol, 4 (4), pp. 631-640, 2019, ISSN: 2452-1094.
Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes.Journal Article
Radiother Oncol, 133 , pp. 62-67, 2019, ISSN: 0167-8140.
Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?Journal Article
Int J Radiat Oncol Biol Phys, 100 (5), pp. 1190-1194, 2018, ISSN: 0360-3016.
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.Journal Article
Eur Urol, 74 (4), pp. 432-441, 2018, ISSN: 0302-2838.